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Women with newly diagnosed breast cancer may have lesions undetected by conventional imaging. Recently contrast-enhanced
magnetic resonance mammography (CE-MRM) showed higher sensitivity in breast lesions detection. The present analysis was
aimed at evaluating the beneﬁt of preoperative CE-MRM in the surgical planning. From 2005 to 2009, 525 consecutive women
(25–75 years) with breast cancer, newly diagnosed by mammography, ultrasound, and needle-biopsy, underwent CE-MRM. The
median invasive tumour size was 19mm. In 144 patients, CE-MRM identiﬁed additional lesions. After secondlook, 119 patients
underwent additional biopsy. CE-MRM altered surgery in 118 patients: 57 received double lumpectomy or wider excision (41 ben-
eﬁcial), 41 required mastectomy (40 beneﬁcial), and 20 underwent contra lateral surgery (18 beneﬁcial). The overall false-positive
ratewas27.1%(39/144).CE-MRMcontributedsigniﬁcantlytothemanagementofbreastcancer,suggestingmoreextensivedisease
in 144/525 (27.4%) patients and changing the surgical plan in 118/525 (22.5%) patients (99/525, 18.8% beneﬁcial).
1.Introduction
The primary objective of any diagnostic imaging modality is
to accurately deﬁne the presence, the type, and the extent of
disease in order to optimize patient management decisions
and best plan therapeutic and surgical interventions. In
women with suspected breast cancer, the aim of diagnostic
imaging is to detect and accurately diagnose malignant tu-
mors and to facilitate the correct choice of therapy, being
mastectomyorbreast-conservingsurgery(e.g.,lumpectomy)
with or without preoperative neoadjuvant chemotherapy.
Thechoicebetweenbreast-conservingsurgeryandmastecto-
my depends on numerous factors including tumour size, lo-
cation and grade, the ratio of tumour size to breast vol-
ume, multifocality or multicentricity of the tumour, and
patient preference. Currently, conventional mammography
andultrasound(US)arestandardimagingtechniquesforthe
detectionandevaluationofbreastdisease[1].Inrecentyears,
contrast-enhanced magnetic resonance mammography (CE-
MRM) has emerged as the most sensitive imaging modal-
ity for the detection and diagnosis of breast lesions [2–5].
Numerous studies have conﬁrmed the superior diagnostic
performance of CE-MRM compared to conventional mam-
mography and US [6–9]. Studies to evaluate the impact of
CE-MRM on patient management decisions have similarly
revealed its superiority compared to standard imaging [10–
13].
The present analysis was aimed at further evaluating the
impact of CE-MRM on surgical decision making compared
with those taken solely on the basis of clinical examination,
conventional mammography, and ultrasound. The potential
impact of CE-MRM on surgical decision making was,
thereafter, evaluated for each patient. The CE-MRM was
consideredtoaccuratelysuggesttheappropriatenessofbreast
conservationimagesclearlywhichdemonstratedtherespect-
ability of the lesion and in which CE-MRM was the only
imaging modality able to do so. CE-MRM was considered to
accuratelysuggestthenecessityofchangingsurgeryplanning2 International Journal of Breast Cancer
when images clearly showed more extensive disease than
otherwise suspected from conventional mammography or
ultrasound. More extensive disease includes larger size of
index cancer,additional fociofcancerinthe same orinother
breastquadrants,andcontralaterallesions.Ourpurposewas
to verify the beneﬁt of preoperative CE-MRM in the surgical
planning in our institution.
2.MaterialsandMethods
This retrospective study includes consecutive patients iden-
tiﬁed from a prospective database from January, 1, 2005 to
November, 30, 2009. A standardized protocol was imple-
mented in the management of all new, biopsy-proven breast
cancer starting in January 2005.
The primary inclusion criterium was a preoperative CE-
MRMinpatientswithhistologicallyconﬁrmedbreastcancer.
The study included women 25 to 75 years of age with a new
primary breast cancer.
Exclusion criteria were mammographic pattern of fatty
breast tissue, pregnancy, claustrophobia, planned bilateral
mastectomy, preoperative chemotherapy, and history of
breast cancer.
All patients underwent mammography and ultrasonog-
raphy. The evaluation of images was performed in consensus
by four observers with 10 years’ experience, respectively,
in interpretation of conventional mammography and breast
ultrasound images. Conventional mammograms and sono-
g r a m sw e r ee v a l u a t e df o rt u m o rd e t e c t i o na n ds i z e .
Needlebiopsywasperformedincaseofsuspiciouslesion,
oftenwithradiographic(USormammographic)guidanceby
14 gauge core needle biopsy (Bard).
Pathological results of core biopsy were in line with UK
and European guidelines [14, 15]. Categories are B1: normal
tissue/unsatisfactory; B2: benign; B3: lesions of uncertain
malignant potential; B4: suspicious of malignancy; B5: (ma-
lignant subclassiﬁed as ductal carcinoma in situ (DCIS) or
invasive cancer) [14, 15].
If the biopsy specimen was positive for malignancy, the
patient was referred to surgeons.
A complete clinical examination was performed and a
preliminarysurgicalplanwasmade.Then,CE-MRMat1.5T
was performed in the eligible patients.
CE-MRM was performed on a 1.5T magnet (Achieva
1.5T Philips) using a bilateral breast surface coil with the
patient in the prone position.
An axial 3D dynamic T1-weighted gradient-echo se-
quence and T2-weighted pulse sequence were employed
with images acquired before contrast agent administration
(precontrast-unenhanced images) and, at 0, 1.5, 3, 4.5, and
6 minutes after the administration of contrast agent (post-
contrast-enhanced images). Postcontrast 3D T1-weighted
gradient-echo dynamic images were acquired after the
administration of 0.1mmol/kg bodyweight of gadopentetate
dimeglumineGd-DTPA(MagnevistBayerScheringPharma)
through an 18 gauge needle cannula positioned in an ante-
cubital vein. Gadopentetate dimeglumine Gd-DTPA was
administered using an automatic injector at a rate of
2mL/sec and was followed by 10mL of saline solution at the
same rate.
The evaluation of images was performed in consensus
by two observers with 13 and 8 years’ speciﬁc experience,
respectively,inCE-MRMinterpretation(approximately1500
MR breast images per year).
If CE-MRM revealed more extensive breast disease, other
thantheindexcancer,thepatientswouldreturnforasecond-
look examination with mammogram and/or US. More
extensive disease included larger size of index cancer, addi-
tional foci of cancer in the same or in other breast quadrants,
and contra lateral lesions.
Secondlookwasperformedbythesameradiologistswho
interpreted the CE-MRM images. If a lesion was conﬁrmed
as suspicious, a new radiographic guided needle biopsy was
performed. CE-MRM-guided biopsy is not available in our
institution.
Whether the patients refused to undergo a core biopsy,
additional surgery was strongly suggested. If the lesion was
not seen on second look, the patient was counselled to
removeitiftheimagewassuspiciousonCE-MRM,ortohave
6-monthfollowupCE-MRMifthelesionwaslessconcerning
in opinion of the attending breast radiologist.
If the pathologic ﬁndings of the CE-MRM-discovered
lesions biopsy specimen were malignant or high-risk pathol-
ogy (atypical ductal hyperplasia (ADH), lobular intraepithe-
lial neoplasia (LIN), papillary lesions, radial scar/complex
sclerosing lesions), the case was reassessed by the same team
of surgeons. A decision was made about the possibility to
change surgical planning. There were three change’s cate-
gories: ﬁrst, from lumpectomy to double lumpectomy or
wider excision, if the new lesions were located in the same
quadrantbutwereseparatedfromtheindexcancerbyatleast
1.0cm of normal-appearing tissue on CE-MRM (multifocal
lesions), or if there was a single additional lesion in other
quadrant than index cancer (bicentric disease), or if it was in
the same quadrant and contiguous with the original cancer
or rounding it, but extended at least 4.0cm beyond the
site of the primary lesion (larger size); second, from breast
conservative surgery to mastectomy, if lesions discovered
were multicentric (more lesions in diﬀerent quadrants), or
if patient was not candidate to conservative surgery (e.g.,
retroareolar, large cancer in little breast); third, contra lateral
surgery, if the lesions identiﬁed were in contra lateral breast.
After surgery, all radiographic and pathologic results
were examined.
In patients with a change of surgery, we analyzed tumour
size and the presence of additional foci on mammographic,
US, CE-MRM, and histologic reports to determine if the
change of treatment was or not appropriate. Appropriate
changes of treatment were deﬁned as those in which patho-
logic report correlates with CE-MRM ﬁndings, but not with
mammography and US. Inappropriate changes of surgery
were those in which CE-MRM predicted a larger lesion or
other foci than mammography or US, but the histological
results conﬁrmed the original mammographic and ultra-
sonographic ﬁndings.International Journal of Breast Cancer 3
Table 1: Breast cancer diagnosis.
N( %)
Positive MX + positive US 401 (76.4)
Positive MX + negative US 70 (13.3)
Negative MX + positive US 54 (10.3)
Total 525 (100)
MX: mammography.
US: ultrasounds.
N: number of patients.
We deﬁned as “false positive” patients, both with positive
MRI and negative core biopsy, than with positive MRI and
negative pathological report after surgery.
The institutional multidisciplinary breast conference of
the Evangelical Hospital of Turin approved the employ of
breast CE-MRM in women with newly diagnosed breast
cancer, and the procedure was scheduled in the routinely
workup of these patients after mammogram and US. The
institutional review board of the Evangelical Hospital of
Turin did not require the approval of patients, nor their
informed consent to review their records on database.
One-year followup was at least required to detect by
mammogram or CE-MRM previously undetected lesions.
Aboutsurveillance,weareinlinewithNCCNpracticeguide-
lines of invasive breast cancer. Physical exam and interval
history every 4–6 months for 5 years, then every 12 months.
Mammogram and US every 12 months (also MRI in recom-
mended cases) [16].
Statistical analysis was performed using the Statistics
Package for Social Sciences, version 15.0 (SPSS Inc., Chicago,
Ill). Categorical variables were evaluated with χ2 analysis.
Resultswereconsideredstatisticallysigniﬁcantwhen P<. 05.
3. Results
During the 5-year study period, 525 women were deﬁned
eligible to undergo bilateral breast CE-MRM, following
inclusion criteria.
The mean age was 51.9 (range 25–75 years). Diagnosis of
breast cancer was made by mammography and ultrasounds
as seen in Table 1.
The median invasive tumour size at study entry was
19mm (range 1–60mm), based on mammography/ultra-
sounds.
In 302/525 patients (57.5%), breast cancer was a palpable
mass and in 223/525 women (42.5%) presented with radio-
graphic ﬁndings.
Lumpectomy, double lumpectomy, or wider excision was
performed for 396/525 patients (75.4%); 129/525 women
(24.6%) underwent mastectomy.
In 67/525 patients (12.8%), the deﬁnitive diagnosis was
ductal carcinoma in situ, whereas in 458/525 (87.2%) cases
was invasive carcinoma (Table 2).
A total of 190/458 patients (41.5%) with invasive cancer
had lymph node-positive disease, preoperative, or after
sentinel node biopsy (Table 3).
Table 2: Histopathologic types.
N (%)
DCIS 67 (12.8)
Invasive carcinomas 458 (87.2)
(i) ductal
(ii) lobular
(iii) others
287 (63)
74 (16)
97 (21)
Total 525 (100)
DCIS: ductal carcinoma in situ.
N: number of patients.
Others: ductal-lobular (49); mucinous (15); tubular (14); medullary (9);
metaplastic (3); papillary (7).
Table 3: Axillary nodes status.
Evaluation N (%)
Positive nodes:
(i) FNAC +
(ii) SNB +
91 (19.9)
99 (21.6)
Negative SNB 268 (58.5)
Total 458 (100)
SNB: sentinel node biopsy.
FNAC: ﬁne needle aspiration cytology.
N: number of patients.
At all, 525 women with a newly diagnosed breast can-
cer underwent CE-MRM according to the study protocol
(Figure 1). CE-MRM ﬁndings were in concordance with
mammogram and/or US in 381/525 patients (72.6%).
In 144/525 patients (27.4%), CE-MRM identiﬁed sus-
picious lesions (Figure 1). In 26 patients, CE-MRM found
additional images that resulted less concerning at second
look with mammogram and/or US (18 cases) and benign at
core biopsy (8 cases). In these cases, preoperative manage-
ment unchanged and patients had six-month followup CE-
MRM recommended.
In 118 patients, CE-MRM detected lesions that the
second look conﬁrmed as concerning. A total of 111 patients
underwent image-guided biopsy (US- or stereotactic-
guided) which found B3, B4, or malignancy in the specimens
[14, 15]. In 7 patients (4 patients who refused to have a new
core biopsy and 3 patients in which the second look did
not identify the additional enhancing lesion detected by CE-
MRM), on the basis of high suspect of CE-MRM imaging,
patients were strongly recommended to undergo to wider
surgery (Figure 1).
CE-MRM altered programmed surgery of newly diag-
nosed breast cancers in 118/525 (22.5%) patients (Table 4).
Fifty-seven patients who were initially candidates for breast-
conserving surgery were upgraded, based on CE-MRM ﬁnd-
ings, to double lumpectomy or to wider excision. In 20/57
patients, CE-MRM found additional foci, and in 37/57 pa-
tients, the size of index cancer was larger.
On the basis of CE-MRM imaging, 41 women required
a mastectomy. 37/41 patients had multicentric cancer CE-
MRM detected, in 4/41 patients, there were a larger lesion
with unfavourable cancer size/breast size ratio.4 International Journal of Breast Cancer
Table 4: Change in surgical management based on CE-MRM.
Treatment change Change Beneﬁcial FP FN
N (%) N (%) N (%) N (%)
(A) Double lumpectomy or
wider excision 57 (48.3) 41 (71.9) 11 (19.3) 5 (8.8)
(B) Mastectomy 41 (34.7) 40 (97.6) 1 (2.4) 0
(C) Contra lateral surgery:
(i) alone
(ii) in addition to (A)
(iii) in addition to (B)
6 (5.1)
8 (6.8)
6 (5.1)
6 (100)
6 (75)
6 (100)
0
1 (12.5)
0
0
1 (12.5)
0
Total 118 (100) 99 (84) 13 (11) 6 (5)
N: number of patients.
FP: false positives.
FN: false negatives.
All patients enrolled in the study received bilateral CE-
MRM, and 20 women had suspicious lesions discovered in
the contra lateral breast (Table 4).
Ofthese20patients,alldemonstratedwithneedlebiopsy,
6 women had programmed operation in the ipsilateral breast
and a new contra lateral surgery; in 14 patients, the surgical
plan changed bilaterally, according to the additional lesions
detected by CE-MRM.
A radiographic-pathologic correlation was performed to
verify whether the change in surgical management based
on CE-MRM was beneﬁcial, owing to better concordance
between CE-MRM and surgical pathologic ﬁndings than
between mammography or US and histological reports.
CE-MRM detected enhanced lesions in 144 cases
(Figure 1). The second look identiﬁed suspicious lesions in
126 cases, and, in 119 patients, an image-guided biopsy (ul-
trasonographic or stereotactic) was performed. Pathologic
reports conﬁrmed an apparent malignancy in the specimens
in 111 patients, whereas 8 patients had benign lesions. The
false-positive rate for biopsy of a CE-MRM-detected lesion
was 8/119 (6.7%). In 18 patients who refused to undergo
core-biopsy after second look, the lesions were considered
by our radiologist as less concerning; these patients had
six-monthCE-MRMfollowuprecommended.Therefore,the
total false-positive rate for second look was 26/144 (18%).
As illustrated in Figure 1, 118 patients had a change in
surgical plan. In 13 patients, change of surgery was inap-
propriate (Table 4), in 11 patients, in which wider excision
was performed, histological reports did not conﬁrm CE-
MRM suggestions, lesions were smaller than 4.0cm, or the
second lesion identiﬁed was near the index cancer (distance
<1.0cm).Inonepatientsinwhichwiderexcisionandcontra
lateral surgery were performed, histology demonstrated that
surgery was appropriate in the breast with index cancer,
but, in contra lateral breast, deﬁnitive diagnosis was benign.
Finally, in one patient who had >4.0cm CE-MRM-detected
lesion, operation was converted to mastectomy, but the sur-
gical histological report did not conﬁrm CE-MRM ﬁndings.
The false-positive rate for surgery was 13/118 (11%).
In summary, the overall false positive rate was 39/144
(27.1%).
CE-MRM
N = 525
= MX/US
N = 381
Programmed
surgery
> MX/US
N = 144
Second look
(US/MX)
N = 144
Core
biopsy
Yes
N = 119
No
N = 25
Radiologic
suspicious
Low
N = 18
Changed
surgery
High
N = 7
B2
N = 8
B3, B4, B5
N = 111
6-month
CE-MRM
6-month
CE-MRM
Figure 1: Additional evaluation based on breast CE-MRM ﬁndings
and change in preoperative management. = MX/US: CE-MRM
report in concordance with MX/US. > MX/US: CE-MRM detects
more or larger lesions. B2: benign lesion; B3: lesion of uncertain
malignant potential; B4: suspiciousnes of malignancy; B5: malig-
nant (B5a: in situ carcinoma (DCIS) or B5b: invasive carcinoma)
[14, 15]. N: number of patients.
AsseeninTable4,insix-womenbreast,CE-MRMdetect-
edadditionalseparatelesions(4patients),oritconﬁrmedthe
presence of the known lesion, but larger (2 patients), which
allowed a wider excision (Table 4). Unfortunately, histology
demonstrated the presence of more extensive disease (6/118,
5% false-negative rate).
Therefore, among 118 patients who had a change in
surgical plan, 99 (84%) were found to have a concordanceInternational Journal of Breast Cancer 5
Table 5: Histopatologic type in the subgroups.
Patients Double lumpectomy/Wider excision∗ Mastectomy∗ Contra lateral
surgery
NN (%) N (%) N (%)
DCIS 67 6 (9) 5 (7.5) 3 (4.5)
IDC 287 31 (10.8) 25 (8.7) 6 (2.1)
ILC 74 10 (13.5) 7 (9.5) 7 (9.5)∗∗
Others 97 10 (10.3) 4 (4.1) 4 (4.1)
DCIS: ductal carcinoma in situ; IDC: inﬁltrating ductal carcinoma; ILC: inﬁltrating lobular carcinoma.
∗Patients with synchronous contra lateral surgery were excluded.
∗∗lobular versus ductal histotype P<. 011.
Others: ductal lobular (49); mucinous (15); tubular (14); medullary (9); metaplastic (3); papillary (7).
Table 6: Negative versus positive nodes in the subgroups.
Double lumpectomy/Wider excision∗ Mastectomy∗ Contra lateral
surgery
Negative nodes (%)
Positive nodes (%)
P value
32/325 (9.8)
25/180 (13.9)
(NS)
16/325 (4.9)
25/180 (13.9)
(P< .0001)
10/335 (3.0)
10/190 (5.3)
(NS)
∗Patients with synchronous contra lateral surgery were excluded.
between CE-MRM ﬁndings and ﬁnal histological reports.
Surgical change was deﬁned in these patients appropriate
and beneﬁcial (Table 4). Forty one of the 57 women (71.9%)
who had an initially planned lumpectomy converted to a
double lumpectomy or to a wider excision based on CE-
MRM were converted appropriately. Forty of 41 patients
(97.6%) who had a lumpectomy converted to a mastectomy
had a beneﬁcial change because CE-MRM correlated with
ﬁnal pathologic report. In the 20 women with contra lateral
CE-MRM-detected lesions, the histological report correlated
with CE-MRM ﬁndings in 19 (95%).
In 163/525 patients, breast cancer was multicentric
(31%). In 88/163 patients, breast cancer was deﬁned as mul-
ticentric before CE-MRM. In seventy-ﬁve patients of 163
(46%), we modiﬁed surgical planning because CE-MRM de-
tected additional foci of breast cancer (including also bicen-
tric disease, in which double lumpectomy was performed).
On univariate analysis, we considered patient age, ra-
diographic ﬁndings, pathologic features, and staging. We
considered patients divided into the three types of changed
surgery. We focused our attention on interesting results (see
Tables 5-7).
We found that patients with ILC (7/64, 9.5%) were more
likely to have contra lateral disease compared with IDC
(6/287, 2.1%); P<. 0001 (Table 5). Patients with positive
nodes (25/180, 13.9%) were converted to mastectomy more
often than women with negative nodes (16/325, 4.9%); P<
.0001 (Table 6). Similarly, we found that patients with multi-
centric disease were more likely to have mastectomy (37/145,
25.5% versus 4/360, 1.1%; P<. 0001) and contra lateral
breast cancer (18/163, 11.0% versus 2/362, 0.5%; P<. 0001),
comparedwithpatientswithunifocalbreastcancer(Table7).
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Figure 2: Curves of disease-free survival local recurrences.Var5 1:
patients with unmodiﬁed surgery after CE-MRM Var5 2: patients
with modiﬁed surgery after CE-MRM P = .97.
The number and the site of recurrences are reported in
Table 8. In our series, as expected and hoped, the number
of ﬁrst local failures was similar in women with converted
surgery, compared with patients with any change of treat-
ment (Figure 2); however, we notice that the number of
distant metastases seems to be higher in cases with modiﬁed
surgery versus unmodiﬁed surgery. Kaplan-Meier survival
analysis (distant disease-free and overall survival) showed
both curves overlapping around 97% at 5 years (Figures 36 International Journal of Breast Cancer
Table 7: Multicentric versus unifocal cancer in the subgroups.
Double lumpectomy/Wider excision∗ Mastectomy∗ Contra lateral
surgery
Multicentric (%)
Unifocal (%)
P value
20/145 (13.8)
37/360 (10.3)
(NS)
37/145 (25.5)
4/360 (1.1)
(P<. 0001)
18/163 (11.0)
2/362 (0.5)
(P<. 0001)
∗Patients with synchronous contra lateral surgery were excluded.
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Figure 3: Curves of disease-free survival distant metastases. Var5 1:
patients with unmodiﬁed surgery after CE-MRM Var5 2: patients
with modiﬁed surgery after CE-MRM P = .002.
and 4). Considering the short followup (median 36 months),
ﬁrm statistical conclusions are hard.
4. Discussion
This retrospective study evaluated the impact of CE-MRM
on the surgical management of 525 consecutive patients of
25–75 years of age with newly diagnosed breast cancer.
Since CE-MRM is performed in all the patients in our
hospital (except patients >75-year old and patients with
mammographic pattern of fatty breast tissue), only few pa-
tients were left out of the study.
Patients were treated following a workup in which our
breast surgeons assessed all patients before CE-MRM. Wom-
en were all revaluated after CE-MRM by the same surgeons
to decide if a change in surgical planning was necessary.
CE-MRM-alteredprogrammedsurgeryin118/525(22.5%)
of patients and, based on ﬁndings founded in the pathologic
specimens, the change of surgery planning was conﬁrmed as
appropriate in 99/118 (84%) of these patients. Thus, 99/525
(18.8%) of women had a favourable change in surgical man-
agement, based on preoperative CE-MRM. Therefore, 5
women must undergo to CE-MRM for 1 to have a beneﬁcial
conversion in surgical plan.
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Figure 4: Curves of overall survival.
Table 8: Site and number of ﬁrst failure after treatment.
Change surgery
No Yes
Site N (%) N (%)
Local 15∗(3.7) 5∗∗(4.2)
Regional 3 (0.7) 1 (0.8)
Contra lateral breast cancer 5∗∗∗(1.2) 0
Distant 11 (2.7) 9 (7.6)
None 373 (91.6) 103 (87.3)
∗Includes one patient with concurrent contra lateral breast cancer and four
patients with synchronous distant metastases.
∗∗Includes one patient with concurrent distant metastases.
∗∗∗Includes one patients with concurrent ipsilateral local failure.
Surgical management, other than the histology and the
sizeofthebreast,isusuallyinﬂuencedbytherealsizeofindex
cancer and by the extent of the disease, indicated by the pres-
ence of multiple malignant foci in the same quadrant or in
diﬀerent quadrants from the main lesions, or by the presence
of contra lateral lesions. CE-MRM has demonstrated that,
despite its suboptimal speciﬁcity, it is able to oﬀer this kind
of information better than conventional radiology.
The ﬁrst risk of CE-MRM is, in fact, the number of false-
positive that may cause unnecessary imaging and biopsies,
and that is a major limitation in the use of this procedure
[17]. In this regard, false positives (and also false negatives)International Journal of Breast Cancer 7
after CE-MRM can be attributed to inherent technological
limitation of CE-MRM, patients characteristics, quality as-
surance failures, and human error [18]. The consequences of
these factors include missed cancers, with potentially worse
prognosis, as well as anxiety and potential harms associated
with interventions for benign lesions [18].
In our series, the overall false-positive rate was 39/144
(27.1%),inwhichCE-MRM-detectedlesionswereultimately
not malignant. In 13/118 (11%) of patients in which change
ofsurgerywasdecided(13/118),theconversionwasinappro-
priate (Table 4).
Furthermore, 11 women were upgraded from lumpec-
tomy to wider excision or double lumpectomy, but histologi-
cal reports did not conﬁrm CE-MRM suggestions. Analyzing
these records in our database, we veriﬁed that four patients
refused to have a guided core biopsy after second look; two
patients had a negative second look with high suspiciousess
of CE-MRM ﬁndings. In these cases, the pathologic speci-
mensrevealedthepresenceofbenignlesions.Theothercases
were B3 and B4 as result of core biopsy. Deﬁnitive pathologic
reports veriﬁed that lesions resulted are not malignant.
In one patient in which ipsilateral wider excision and
contra lateral surgery were performed, histology demon-
strated that surgery was appropriate in the breast with index
cancer, but, in contra lateral breast ﬁnal diagnosis was LIN 1.
Moreover, in one patient, an unnecessary mastectomy
was programmed, because the lesion was overestimated by
CE-MRM, and, in the histological specimen, the presence of
a LIN 1 near the index cancer was veriﬁed.
Considering false negatives, in six of 118 women, CE-
MRM detected additional lesions, which allowed a wider
excision. These patients were borderline candidates for
breast-conserving therapy, and, after an exhaustive coun-
selling with them, the decision to attempt a wider excision
was made. Unfortunately, histology demonstrated the pres-
ence of more extensive disease (5% false-negative rate), and
a subsequent mastectomy was performed.
Numerous reports showed that CE-MRM can detect
additional foci in a substantial number of women with a
new diagnosis of breast cancer [6–9]. Moreover, numerous
nonrandomized studies have attempted to evaluate the eﬀect
of CE-MRM on surgical treatment and planning [10–13].
The only evidence from a prospective randomized trial on
the impact of CE-MRM on surgical management derived
from the COMICE study [19], a controlled randomized
trial that was designed to measure the reexcision rate as its
primary endpoint (Turnbull et al., 2010). In this trial 1,625
women were randomly evaluated before surgery with breast
CE-MRM or not [19]. Reexcision rates were quite similar
in women randomized to receive conventional assessment
(19.3%) or to receive CE-MRM in addition to standard im-
aging (18.8%); NS [19].
Previous reports have also described the identiﬁcation
of previously undetected, synchronous lesions in the contra
lateral breast using CE-MRM in an average of 5% of women
with a recent diagnosis of breast cancer [20–22].
The most of CE-MRM-detected contra lateral breast
cancers appear to early stage disease, as indicated in a recent
review [23], and, in approximately 2/3 of cases, the speci-
mens were positive for invasive cancer [23, 24].
In patients with invasive lobular carcinoma (ILC), the
coexistence of other invasive malignant foci, identiﬁed by
breastCE-MRM,apartfromtheindexlesionintheipsilateral
breast reached 32% in a recent meta-analysis [25]. Moreover,
the detection rate of contra lateral ILC is another 7% of
patients by CE-MRM only [25].
Our overall detection rate of contra lateral breast cancer
was 20/525 (3.8%). All the contra lateral lesions CE-
MRM detected were guided-biopsy proven and only one
of them were overestimated. CE-MRM (Table 5) identiﬁed
bilaterality in 3/67 (4.5%) of DCIS in 6/287 (2.1%) of IDC
and in 7/74 (9.5%; P<. 0001) of ILC, respectively. Finally,
the number of the CE-MRM-detected contra lateral breast
cancers was unrelated to nodal status (Table 6). The fact that
change in treatment was considered correct, as veriﬁed by
pathologic ﬁndings in the specimen, in 19/20 (95%) of cases
of contra lateral surgery (Table 4), shows that breast cancer,
and especially ILC, is often more extensive than appreciate
on conventional imaging.
Our study shows that the CE-MRM can improve the
detection of other malignant lesions (ipsilateral and contra
lateral) when added to a conventional imaging (mammo-
gram and US) at the time of the initial diagnosis of breast
cancer. The current cost of CE-MRM precludes its wide-
spread use in general population, but this imaging tool
appears to improve the detection of cancer in women at in-
creased risk, such as women with a recent diagnosis of breast
cancer,andanumberneededtotreatof5isreasonableinour
opinion.
IfCE-MRMisperformed,thefalse-positiverateindicates
that abnormal ﬁndings should be investigated with image-
guided core biopsy to establish a diagnosis before surgical
treatment, as emphasized in a recent review [26].
The second risk of this approach to local staging the
breast is that more women being treated with more radical
surgery without a demonstrated improvement in surgical
outcomes or prognosis.
Basedontheresultsofcontrolledclinicaltrialswithmor-
talityastheendpoint,breastconservationtherapy(BCT)and
mastectomy confer equivalent risk to the patient [27–29]. As
stated by Orel and Schnall [4], the 25–36% of local recur-
rence rate in the absence of radiotherapy and chemotherapy
corresponds to the frequency of multifocal and multicentric
tumours found only with conventional imaging [4]. The
potential 10-year recurrence rate after breast-conserving
therapy followed by standard adjuvant therapies (radiation
therapy, chemotherapy, and hormonal therapy) would be 9-
10% [30]. Moreover, the absolute risk of contra lateral breast
cancer in women with a personal history of breast cancer
is up to 3% of synchronous disease, whereas 7% of women
will be diagnosed with metachronous disease [22]. This risk
is signiﬁcantly higher than that of the general population
[31]. In this regard, adjuvant therapies (local and systemic)
play a key role in achieving local control in women treated
with breast-conserving surgery. Thus, the goal of breast-
conserving therapy is to achieve good local control, and to8 International Journal of Breast Cancer
provide women who wish to conserve their breast a good
cosmetic result.
Some argue that any increase in the rate of mastectomy
prompted by CE-MRM ﬁndings would represent a setback
in the standard of care [32, 33]. And since radiation therapy
is presumed to eradicate or delay the progression of residual
disease in most women who undergo conservation therapy,
preoperative CE-MRM would have little or no impact on
r a t e so fr e c u r r e n c eo rd e a t h[ 32].
On the other hand, the upper threshold amount of
residual disease that can be eradicated by radiation therapy is
not yet well established. Although the rate of recurrence after
breast conservation is low, it is not zero, and each patient
should be oﬀered the best possible chance for successful
treatment. Detecting widespread disease can obviate inap-
propriate attempts at conservation, in which both lumpec-
tomy with positive margins and reexcision with positive
margins are carried out before the full extent of the disease
burden is understood. A staging CE-MRM examination
showing only a single cancer lesion may permit the patient to
chooseconservationtherapywithadegree ofconﬁdencethat
no macroscopic disease will be missed at surgery [34]. About
our false positives, as yet explained above, the pathologic
reports described four cases of ADH, and two cases of LIN 1.
In women with ADH a review of literature suggests a 4- to 5-
fold increased risk of invasive breast cancer, compared with
a 6- to 10-fold risk ALH/LIN [35]. With regard to lobular
neoplasia, the subsequent invasive cancer may be ipsilateral
or contra lateral, and more than 50% of these diagnoses
occur more than 15 years after the original diagnosis of
lobular neoplasia [36, 37]. Thus, in our opinion, the excision
of these lesions that were considered clinical risk factors of
breast cancer was absolutely correct.
Therefore, if we believe that it is important to clear
lumpectomy margins of breast disease (from atypical hyper-
plasia to in situ and microinvasive carcinoma) to reduce the
risk of local recurrence, it should follow that small foci in
bothbreastdetectedonCE-MRMalsowarrantidentiﬁcation
and excision.
After a median followup of 36 months, we reported
5/118 (4.2%) versus 15/407 (3.7%) (NS) local recurrences in
women with converted surgery, compared with patients with
any change of treatment (Figure 2). However, the two popu-
lationsdiﬀeredasregardthemetastaticrisk, somuchastobe
able to undo the eﬀect of possible local beneﬁt. In our series,
we observed higher rates of larger cancers > pT1 (39/118,
33.0% versus 92/407, 22.6%) and of nodal involvement
(58/118, 49.1 versus 144/407, 35.4; P<. 0001) in cases with
modiﬁed versus unmodiﬁed surgery. This condition could
carry out the higher rate of distant recurrences. In fact, we
observed up to this time 9/118 (7.6%) events in former
group versus 11/407 (2.7%) in the latter. These few events
do not allow us to distinguish any subgroup of risk, that is
multicentricity versus larger size of tumour. Kaplan-Meier
survival analysis showed both curves overlapping around
97% at 5 years (Figures 3-4). As reported elsewhere [12],
larger tumour size is an independent factor of a beneﬁcial
change in surgical management of newly diagnosed breast
cancer in patients who undergo CE-MRM (odds ratio 1.66;
95% C.I., 1.04–2.66) [12].
Anyway, before to say that CE-MRM have little or no
impact on local recurrence rate and on survival rate, because
women are at higher risk of distant metastases, the number
of observations and the followup should be implemented.
5. Conclusions
The use of CE-MRM results in a beneﬁcial change in surgical
management in 99/525 (18.8%) of patients. Additional
malignant lesions are detected in about one patient every ﬁve
who undergo CE-MRM.
These data suggest that CE-MRM plays a role in the
staging evaluation of newly diagnosed breast cancers.
Our experience conﬁrms that, when needle-biopsy was
missed, the suspiciousness of CE-MRM-imaging ﬁndings
was not suﬃcient to advise a change in surgical planning (six
high suspicious CE-MRM-detected lesions without preoper-
ativehistologicalconﬁrmationresultedbenignaftersurgery).
Thus, we conclude that guided needle biopsy is always rec-
ommended to verify additional CE-MRM-detected lesions.
This study has some limitation to be addressed. It is a
retrospective report of consecutive patients with a proven
diagnosis of newly breast cancer. The number of patients is
quite large, but the median followup is not so long to make
ﬁrm statistical conclusions.
Therefore, future research is mandatory to explore the
value of CE-MRM in the improvement of surgical outcome
and prognosis by decreasing the need for reoperation and
lowering recurrent rates.
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